پیوندهای مفید
آمار
| تعداد نشریات | 20 |
| تعداد شماره‌ها | 1,230 |
| تعداد مقالات | 11,205 |
| تعداد مشاهده مقاله | 78,023,352 |
| تعداد دریافت فایل اصل مقاله | 103,587,902 |
MicroRNA-146a Inhibits Progression and Immune Evasion in Diffuse Large B-cell Lymphomas by Targeting Programmed Cell Death Ligand 1 | ||
| Iranian Journal of Immunology | ||
| دوره 22، شماره 1، خرداد 2025، صفحه 34-46 اصل مقاله (1.95 M) | ||
| نوع مقاله: Original Article | ||
| شناسه دیجیتال (DOI): 10.22034/iji.2025.104027.2874 | ||
| نویسندگان | ||
| Yan Li* ؛ Xiang Wang؛ Kuannv Yang | ||
| Department of Hematology, Hainan Cancer Hospital, Haikou City 570312, Hainan Province, China. | ||
| چکیده | ||
| Background: Earlier studies have highlighted the involvement of miRNA146a in tumor suppression indicating its potential to inhibit the progression of diffuse large B-cell lymphoma (DLBCL). Objective: To identify programmed death-ligand 1 (PD-L1) as a candidate for further research, as it plays a key role in regulating immune checkpoints in cancer and is associated with the involvement of miRNA146a in immune regulation and the response to inflammation. Materials and Methods: The expression of miR-146a and PD-L1 in DLBCL cells was detected using qPCR analysis. Subsequently, DLBCL cells (OCI-Ly-3 and OCI-Ly-7) were treated with either the miR-146a mimic or a blank plasmid. To assess immune evasion, DLBCL cells were cocultured with peripheral blood mononuclear cells, CD8+ T cells, or cytokine-induced killer cells. Furthermore, the target gene of miR-146a was predicted and validated. Results: Compared to the normal B-cell line (NCB), the level of miR-146a was significantly lower in DLBCL cells. Additionally, overexpression of miR-146a significantly reduced DLBCL viability, invasion, and immune evasion while simultaneously promoting apoptosis. Our findings also confirmed that miR-146a targeted PD-L1. Finally, the upregulation of PD-L1 notably reversed the tumor suppressive effects of miR-146a on DLBCL. Conclusion: Our study indicates that miR-146a inhibits the progression of DLBCL by enhancing antitumor immunity through the targeting of PD-L1. The therapeutic potential of this miRNA in lymphoma is highly desirable. | ||
| کلیدواژه‌ها | ||
| Antitumor immunity؛ Cytokine-induced killer؛ Diffuse large B-cell lymphoma؛ DLBCL cells؛ Tumor | ||
|
آمار تعداد مشاهده مقاله: 524 تعداد دریافت فایل اصل مقاله: 340 |
||